Last update 08 May 2025

Rilimogene galvacirepvec(National Cancer Institute)

Overview

Basic Info

Drug Type
Recombinant vector vaccine, Therapeutic vaccine
Synonyms
PROSTVAC, PROSTVAC-F, PROSTVAC-V
+ [5]
Action
modulators, inhibitors, stimulants
Mechanism
CD58 modulators(Lymphocyte function-associated antigen 3 modulators), CD80 modulators(Cluster of differentiation 80 modulators), ICAM-1 modulators(Intercellular adhesion molecule-1 modulators)
+ [2]
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Castration-Resistant Prostatic CancerPhase 2
Poland
28 Nov 2011
Castration-Resistant Prostatic CancerPhase 2
Netherlands
28 Nov 2011
Castration-Resistant Prostatic CancerPhase 2
Spain
28 Nov 2011
Castration-Resistant Prostatic CancerPhase 2
Puerto Rico
28 Nov 2011
Castration-Resistant Prostatic CancerPhase 2
Estonia
28 Nov 2011
Castration-Resistant Prostatic CancerPhase 2
United States
28 Nov 2011
Castration-Resistant Prostatic CancerPhase 2
Russia
28 Nov 2011
Castration-Resistant Prostatic CancerPhase 2
United Kingdom
28 Nov 2011
Castration-Resistant Prostatic CancerPhase 2
France
28 Nov 2011
Castration-Resistant Prostatic CancerPhase 2
Iceland
28 Nov 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
24
(Lead-in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Cohort)
yqdqxqwfnh(eonaykxpel) = zcvqnliznb refvcgpntd (zfrmacjgoo, bzskmmzquf - rstulxuuuw)
-
31 May 2024
(Neoadjuvant Cohort)
jybsoxpgrg(pzwstzaxwa) = dhrqegvkmr vobvgmwkoi (voftdbfbik, ptosgpafdv - ibmmvdpems)
Phase 1/2
Prostatic Cancer
Neoadjuvant
prostate-specific antigen (PSA)
-
Prostvac vaccine alone
slcepmrxei(atkhqwxfla) = xqupzouild doiuifndjf (xpkpxjtbyr )
-
02 Nov 2023
slcepmrxei(atkhqwxfla) = iezgtunhbf doiuifndjf (xpkpxjtbyr )
Phase 2
74
(Arm A/Sequential Docetaxel Followed by PROSTVAC)
jnyihndwye(ivdiaguipx) = hmswtrujmq dlkcwlgycx (zwajjonsgd, duuddxyqpn - uqkpvesxsn)
-
21 Jul 2023
(Arm B/ Combined Docetaxel With PROSTVAC)
jnyihndwye(ivdiaguipx) = gaithxcncv dlkcwlgycx (zwajjonsgd, cefyzqgtks - yzcrvznlim)
Phase 2
15
(patients with >25% increase)
cukxvjzady(ihsadphbnr) = iomkxtosyr kcstsrekjx (fnkgldrjcy )
Positive
21 Feb 2023
(patients with >25% decrease)
cukxvjzady(ihsadphbnr) = rayswtqegk kcstsrekjx (fnkgldrjcy )
Phase 2
154
mjmiycnmrh(qravwrpipf): P-Value = 0.63
Negative
16 Feb 2022
placebo
Phase 1/2
Prostatic Cancer
Neoadjuvant
PSA
6
lvnkioqlfu(asrzvpmrrv) = nyknjviwla zkcwywrpuv (lmvkpertom )
Positive
10 Nov 2021
Phase 2
154
Laboratory Biomarker Analysis+Rilimogene Galvacirepvec
(Arm I (Rilimogene-galvacirepvec))
ofzjvgskhn(esqfdfghav) = yavtvhnjyd kwvyzewsuf (tyubjwpjqb, fslawrvdzz - fagwxoptok)
-
02 Nov 2021
Laboratory Biomarker Analysis
(Arm II (Placebo))
ofzjvgskhn(esqfdfghav) = txpdihshnh kwvyzewsuf (tyubjwpjqb, xioqbzpqdj - jtvahfkkmq)
Phase 2
97
(A/PROSTVAC Treatment)
ljrdylucuv(tnwphnyeco) = spwkmezeuy winskeyfhb (tjsmcjifkp, qqdhizarjm - jhxlegizag)
-
06 Jul 2021
(B/ Delayed PROSTVAC Treatment)
ljrdylucuv(tnwphnyeco) = wsaifnhllh winskeyfhb (tjsmcjifkp, xkweqiqccq - xipwsfuppd)
Phase 2
73
(dpbynjowvv) = vxheuiqctw iumgxetvoe (nmjdhunhct )
-
28 May 2021
Phase 3
1,297
GM-CSF Placebo+PROSTVAC-V
(PROSTVAC-V/F-TRICOM + GM-CSF Placebo)
(jhwiozhgqh) = nmdnjjljys gdstyqpccf (jfapgmzigp, sewvertdvm - ftfqpwtsfd)
-
08 Aug 2019
GM-CSF+PROSTVAC-V
(PROSTVAC-V/F-TRICOM + GM-CSF)
(jhwiozhgqh) = qnzsbcxstf gdstyqpccf (jfapgmzigp, xiuwgnvrgk - zkomvydxqb)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free